阿普斯特全网公布的2025年最新价格

Apremilast is a selective inhibitor of phosphodiesterase 4 (PDE4) that has demonstrated significant efficacy in the treatment of psoriatic arthritis and plaque psoriasis. In 2025, Apremilast's network-wide prices will vary depending on factors such as version, region, and sales channel, providing patients with diverse choices.

The latest price for 2025 announced by Apremier on the entire website

There are multiple versions on the market, including the version produced by Glenmark in India and the version produced by Celgene in the United States. The price differences between these different versions are significant.

Apremilast has been launched in China and has been included in medical insurance. The winning price of medical insurance ranges from approximately US$51 to US$70. The price after reimbursement will be lower and needs to be calculated according to the specific reimbursement ratio.

Apremilast produced by Glenmark in India has two specifications, with different specifications and different prices. The price of a box of 30mg*30 pills is about US$22, and the price of a box of 30mg*60 pills is about US$32.

The above prices are for reference only. When choosing, patients should weigh the pros and cons and make a decision based on their own financial situation and doctor's advice.

Reasons for price differences

The reasons for Apremilast’s price differences mainly include production costs, brand effects, regional differences and sales channels. The lower price of the Indian version of Apremilast is related to its lower production costs and looser price control policies. The American Celgene version of Apremilast is relatively expensive due to its high brand awareness, large R&D investment and strict regulatory requirements.

Purchase Suggestions

When purchasing Apremilast, patients should choose formal channels to ensure the quality of the drug. At the same time, you can also pay attention to some medical service institutions or overseas pharmacies to get better prices.

Apremilast Medication Guide

Apremilast is an oral medication used to treat active psoriatic arthritis and moderate to severe plaque psoriasis in adults. Its medication guide includes usage and dosage, medication precautions, and adverse reaction treatment.

Dosage

The recommended dose of Apremilast is 30 mg twice daily. To reduce the risk of gastrointestinal symptoms, patients should follow titration to the recommended dose. For patients with severe renal impairment, the recommended dose is 30 mg once daily.

Drug Precautions

It is necessary to regularly monitor body weight when using Apremilast. If unexplained or clinically significant weight loss occurs, timely evaluation and discontinuation of the drug should be considered. Avoid concurrent use with other drugs that induce cytochrome P450 enzymes to avoid loss of efficacy.

Contraindicated groups for Apremilast

Although Apremilast is effective, it is not suitable for all patients. The following groups should avoid using Apremilast:

People allergic to Apremilast

Patients with known severe allergies to Apremilast or similar drugs should not use this drug. Allergic reactions may include skin rash, shortness of breath, facial swelling and other symptoms, and in severe cases, may be life-threatening.

Patients with severe hepatic impairment

Apremilast is metabolized in the liver and therefore should be avoided in patients with severe hepatic impairment. The impact on liver function may slow down the metabolism of drugs in the body and increase the retention time of drugs in the body, thus increasing the risk of adverse reactions in patients.

Pregnant and lactating women

Although there is currently insufficient research evidence to show that Apremilast is harmful to the fetus or breast milk, to avoid potential risks, pregnant and lactating women should use it with caution. Before use, you should consult your doctor and weigh the pros and cons.

The safety and effectiveness of Apremilast in children and adolescents under 18 years of age have not been established and use should be avoided.